1. Home
  2. CRBP vs RILY Comparison

CRBP vs RILY Comparison

Compare CRBP & RILY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • RILY
  • Stock Information
  • Founded
  • CRBP 2009
  • RILY 1973
  • Country
  • CRBP United States
  • RILY United States
  • Employees
  • CRBP N/A
  • RILY N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • RILY Investment Managers
  • Sector
  • CRBP Health Care
  • RILY Finance
  • Exchange
  • CRBP Nasdaq
  • RILY Nasdaq
  • Market Cap
  • CRBP 96.5M
  • RILY 91.8M
  • IPO Year
  • CRBP N/A
  • RILY 2007
  • Fundamental
  • Price
  • CRBP $8.22
  • RILY $4.23
  • Analyst Decision
  • CRBP Strong Buy
  • RILY
  • Analyst Count
  • CRBP 10
  • RILY 0
  • Target Price
  • CRBP $53.56
  • RILY N/A
  • AVG Volume (30 Days)
  • CRBP 215.8K
  • RILY 1.1M
  • Earning Date
  • CRBP 08-05-2025
  • RILY 08-14-2025
  • Dividend Yield
  • CRBP N/A
  • RILY N/A
  • EPS Growth
  • CRBP N/A
  • RILY N/A
  • EPS
  • CRBP N/A
  • RILY N/A
  • Revenue
  • CRBP N/A
  • RILY $854,383,000.00
  • Revenue This Year
  • CRBP N/A
  • RILY N/A
  • Revenue Next Year
  • CRBP $270.04
  • RILY N/A
  • P/E Ratio
  • CRBP N/A
  • RILY N/A
  • Revenue Growth
  • CRBP N/A
  • RILY N/A
  • 52 Week Low
  • CRBP $4.64
  • RILY $2.67
  • 52 Week High
  • CRBP $61.90
  • RILY $20.80
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 54.23
  • RILY 82.09
  • Support Level
  • CRBP $7.26
  • RILY $2.90
  • Resistance Level
  • CRBP $7.90
  • RILY $4.34
  • Average True Range (ATR)
  • CRBP 0.53
  • RILY 0.24
  • MACD
  • CRBP -0.01
  • RILY 0.15
  • Stochastic Oscillator
  • CRBP 78.59
  • RILY 92.80

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About RILY B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

Share on Social Networks: